A study revealed that many middle-aged individuals free of cardiovascular risk factors (CVRF) have atherosclerosis. Atherosclerosis presence and extent was associated with low-density lipoprotein cholesterol (LDL-C) and glycosylated hemoglobin levels (HbA1c). The study evaluated 1,779 (45.0 ± 4.1 years old, 50.3% women) participants. CVRF freedom was defined as no current smoking and untreated blood pressure <140/90 mm Hg, fasting glucose <126 mg/dl, total cholesterol <240 mg/dl, LDL-C <160 mg/dl, and high-density lipoprotein cholesterol ≥40 mg/dl. A subgroup with optimal CVRFs (n = 740) was also defined as having blood pressure <120/80 mm Hg, fasting glucose <100 mg/dl, HbA1c <5.7%, and total cholesterol <200 mg/dl. Subclinical atherosclerosis (carotid, iliofemoral, and abdominal aortic plaques or coronary artery calcification) was present in 49.7% of CVRF-free participants. In addition to male sex and age, LDL-C was independently associated with atherosclerosis presence and extent, in both the CVRF-free and CVRF-optimal groups (odds ratio [×10 mg/dl]: 1.14 to 1.18). Atherosclerosis presence and extent was also associated in the CVRF-free group with glycosylated hemoglobin levels. The findings are consistent with previous studies. The findings suggest that additional factors are involved in atherogenesis; while LDL-C may play critical role, slightly increased HbA1c levels are linked to atherosclerosis, particularly in combination with other risk factors in atherogenesis. Source: http://www.onlinejacc.org/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.